Dose is the variable that changes everything. The same molecule — psilocybin — produces nothing, a cognitive shimmer, a full mystical journey, or a complete dissolution of ego depending on how much you take. Clinical trials have spent decades mapping this landscape. Here is what they found.
Why Dosing Science Matters
For decades, the only dosing data came from self-reports and underground guides. Terence McKenna’s “heroic dose” of 5 dried grams sat at one end. A microdose of 0.1–0.3g sat at the other. Everything in between was folklore.
The clinical research era changed this. From 2006 to 2024, researchers at Johns Hopkins, NYU, Imperial College London, and the University of Zurich conducted controlled trials using precise, weighed doses of synthetic psilocybin — not mushrooms — administered under standardised conditions. For the first time, we have dose-response data.
The findings are not simple. Psilocybin does not behave like most pharmacological agents, where more dose equals more effect in a linear curve. Its effects are shaped by set, setting, and individual neurochemistry. But the dose tiers below represent the best current science on what to expect at each level.
The Five Dose Tiers
Tier 1: Microdose — 0.05g to 0.3g dried (1–3mg synthetic)
Sub-perceptual. No visuals, no dramatic mood shift. Users report improved focus, emotional fluency, and reduced rumination. The Beckley Foundation’s 2021 self-blinded study (Szigeti et al.) found modest positive effects on wellbeing — but so did the placebo group. Effect size: small. Mechanism: unclear. Current evidence does not strongly support therapeutic use at this tier for clinical populations.
Tier 2: Low Dose — 0.5g to 1g dried (5–10mg synthetic)
Perceptual threshold. Enhanced sensory perception, mild euphoria, increased emotional openness. Suitable for therapeutic exploration in carefully supported settings. Not used in landmark clinical trials. Duration: 3–4 hours. Anxiety risk is low at this tier. Useful for first exposure or for those with high baseline anxiety.
Tier 3: Moderate Dose — 1.5g to 3.5g dried (15–25mg synthetic)
This is the clinical gold standard. Johns Hopkins trials used 20–30mg. At this range: closed-eye visuals, time distortion, deep emotional processing, mystical features in a significant proportion of participants. Griffiths et al. (2016) found 61% of participants at 30mg had a “complete mystical experience” on the MEQ-30 scale. This tier produces the largest therapeutic outcomes in controlled research. Duration: 4–6 hours.
Tier 4: High Dose — 4g to 5g dried (30–40mg synthetic)
Immersive. Full visual geometry, ego dissolution in a substantial proportion of users, profound emotional intensity. Used in some trials for existential distress in terminal illness patients. Carhart-Harris et al. (2021) used 25mg in the COMPASS Pathways trial — that arm produced significantly better outcomes on the MADRS depression scale. At this level, the therapeutic benefit is high but so is the demand on the therapeutic container.
Tier 5: Heroic Dose — 5g+ dried (40mg+ synthetic)
Ego dissolution territory. McKenna’s “heroic dose” sits here. No clinical trials have used doses at this level. Self-reports describe complete dissolution of the self-other boundary. This tier carries the highest risk of difficult experiences and is not part of any evidence-based protocol. It exists in the ethnobotanical tradition, not the clinical one.
Set, Setting, and the Dose Multiplier
Every clinical protocol pairs dose with preparation. Johns Hopkins requires 8 hours of preparatory therapy before the session. The reason: at moderate to high doses, psychological factors amplify or dampen the psilocybin effect in ways that can shift the entire experience. Johnson et al. (2018) coined the phrase “set and setting multiplier” — the same 25mg dose in an anxious, unsupported context produces a very different outcome than the same dose in a prepared, supported therapeutic container.
The Inner Work Demands the Right Foundation
Intentional altered states require preparation, container, and integration. OOTW psilocybin products are formulated for those who approach this work with seriousness — and understand what the neuroplasticity window demands.
Shop OOTW Psilocybin →Body Weight and Dose Calculation
Some researchers have moved toward weight-adjusted dosing. The standard formula used in several trials is 0.3mg/kg body weight for a moderate dose. A 70kg individual receives approximately 21mg — within the clinical sweet spot. A 90kg individual receives 27mg. Weight-adjusted dosing reduces variability and is increasingly favoured in academic settings.
The Threshold for Mystical Experience
Much of psilocybin’s therapeutic effect appears to be mediated by the mystical experience — measured by the Mystical Experience Questionnaire (MEQ-30). Griffiths et al. (2016) showed that the MEQ score at 30mg predicted long-term positive outcomes at 6 months. Participants who scored above the threshold on the MEQ showed significantly greater improvements in wellbeing, life meaning, and openness.
The mystical experience threshold appears to lie between 20–30mg in most individuals. Below this range, therapeutic outcomes are less robust. This is why clinical protocols do not use sub-threshold doses for primary treatment sessions.
Tolerance and Session Spacing
Psilocybin produces rapid pharmacological tolerance. A second full dose taken within 48–72 hours will produce a dramatically reduced effect. Most clinical protocols space sessions by at least 2 weeks — not for safety, but for integration. The psychological processing that follows a session is as important as the session itself.
Contraindications: When Dose Does Not Matter
No dose of psilocybin is appropriate for individuals with personal or first-degree family history of schizophrenia, bipolar I disorder, or psychosis. The 5-HT2A agonism that produces psilocybin’s effects can trigger or exacerbate psychotic episodes in vulnerable individuals. All landmark clinical trials screened out this population. Lithium, MAOIs, and certain SSRIs interact with psilocybin in clinically significant ways and must be accounted for in any protocol.
The Psilocybin Dosing Matrix: What Changes at Each Tier
The dose-response relationship for psilocybin is best understood not as a single curve but as a matrix of effects that shift qualitatively, not just quantitatively, as dose increases. At sub-threshold doses, changes are cognitive and emotional — subtle shifts in perspective, reduced default mode network activity, mild increases in neuroplasticity markers. At the moderate clinical dose range, the shift becomes phenomenological: time perception distorts, boundaries between self and environment soften, autobiographical memory becomes more fluid and accessible. At high doses, the phenomenology crosses another threshold into ego dissolution — a state where the ordinary sense of being a separate self temporarily ceases.
Understanding this matrix matters because therapeutic researchers have hypothesised that the therapeutic mechanism shifts across dose tiers. At low doses, improvement may come primarily from increased neuroplasticity and reduced default mode network rigidity — allowing new thought patterns to form. At moderate doses, the mystical experience itself appears to be the mechanism: the temporary dissolution of the narrative self creates a window in which core beliefs, fears, and emotional patterns can be re-examined without the usual defensive structures in place. This is why the MEQ-30 score predicts outcome more powerfully than the dose itself.
Psilocybin vs Mushrooms: The Conversion Problem
Converting between synthetic psilocybin milligrams and dried mushroom grams is more complex than it appears. Psilocybin mushrooms (most commonly Psilocybe cubensis) contain 0.2–2% psilocybin by dry weight depending on the strain, growing conditions, drying method, and storage time. A batch of “average” cubensis at 0.6% psilocybin would give approximately 6mg per gram — meaning 3g of mushrooms contains roughly 18mg of psilocybin, within the clinical range. But a high-potency strain at 1.5% changes the calculation dramatically: 3g now delivers 45mg, well into territory that exceeds clinical trial protocols.
This variability is precisely why clinical research moved to synthetic psilocybin. It is also why the common practice of converting trial doses to mushroom equivalents should be treated with significant caution. The “3.5g is about 30mg” conversion is an average, not a reliable guide. Variance between batches, strains, and even individual caps within the same batch can be substantial.
The Integration Window: Why Dose Alone Is Never Enough
Every major clinical protocol treats the session as one node in a therapeutic arc, not as the therapeutic act itself. The Johns Hopkins protocol involves extensive pre-session preparation (typically 6–8 hours spread over multiple meetings), the dosing session itself (6–8 hours), and multiple integration sessions in the weeks following. The MAPS protocol for MDMA-assisted therapy uses a similar structure, and psilocybin researchers have adopted the same logic.
The theoretical basis is neuroplasticity. Both functional MRI and receptor binding studies suggest that psilocybin administration is followed by a period of heightened neuroplasticity — a window lasting days to weeks during which the brain is more receptive to new learning, emotional processing, and the formation of new associative patterns. The Carhart-Harris neuroplasticity hypothesis (2021) proposes that this window is when the genuine therapeutic work occurs, and that the quality of integration — the quality of the psychological work done in this window — determines whether the acute experience translates into lasting change.
This is not incidental. It means that dose selection cannot be separated from context selection. Choosing a 30mg session outside a therapeutic container — without preparation, without a trained guide, without integration support — is not the same intervention as a 30mg session within one. The dose is necessary. It is not sufficient.
What the 2022 NEJM Depression Trial Tells Us About Dose
The COMPASS Pathways Phase 2b trial (Goodwin et al., 2022), published in the New England Journal of Medicine, remains the largest controlled psilocybin trial to date. It enrolled 233 participants across 22 sites and used three dose conditions: 1mg (active placebo), 10mg, and 25mg. The results at three weeks post-treatment were unambiguous: the 25mg group showed a mean reduction of 6.6 points on the MADRS depression scale above the 1mg group. The 10mg group showed a 2.5-point difference — statistically significant, but clinically modest.
This trial is critical for dosing science because it provided the first large-sample dose-comparison data for a specific indication (treatment-resistant depression). The dose-response relationship was clear: 25mg outperformed 10mg by a factor of nearly three on the primary outcome. The implication for clinical protocol design is that the 25–30mg range is not just conventional but evidence-supported as the minimum effective dose for robust antidepressant effects in this population.
Choosing Your Protocol
The evidence supports a moderate-to-high dose (20–30mg synthetic, or approximately 2.5–3.5g dried) in a structured, prepared context with an experienced guide or therapist for therapeutic purposes. For first exposure, a low-to-moderate dose (10–15mg, or 1–2g dried) in a safe, supported environment allows meaningful experience with lower risk of overwhelming material.
Above all: dose without container is incomplete. The clinical evidence does not just show that psilocybin works. It shows that psilocybin works within a protocol. The preparation, the intention, the integration — these are not supplementary. They are the mechanism.
Dose is the key. The container is the lock.